{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.9","upperLimit":"5.4","value":"5.1"},{"groupId":"OG001","lowerLimit":"3.9","upperLimit":"49.1","value":"6.0"},{"comment":"Upper limit was not estimable because of insufficient number of participants with events prior to censoring.","groupId":"OG002","lowerLimit":"4.9","upperLimit":"NA","value":"6.1"},{"comment":"Upper limit was not estimable because of insufficient number of participants with events prior to censoring.","groupId":"OG003","lowerLimit":"6.0","upperLimit":"NA","value":"27.1"},{"groupId":"OG004","lowerLimit":"5.3","upperLimit":"10.4","value":"6.1"},{"comment":"Upper limit was not estimable because of insufficient number of participants with events prior to censoring","groupId":"OG005","lowerLimit":"11.3","upperLimit":"NA","value":"17.1"},{"groupId":"OG006","lowerLimit":"5.0","upperLimit":"14.1","value":"12.3"},{"groupId":"OG007","lowerLimit":"2.1","upperLimit":"11.3","value":"11.3"},{"groupId":"OG008","lowerLimit":"5.1","upperLimit":"43.0","value":"11.0"},{"groupId":"OG009","lowerLimit":"9.3","upperLimit":"23.0","value":"18.1"},{"comment":"Median and upper limit were not estimable because of insufficient number of participants with events prior to censoring.","groupId":"OG010","lowerLimit":"5.1","upperLimit":"NA","value":"NA"},{"groupId":"OG011","lowerLimit":"5.3","upperLimit":"17.0","value":"10.1"},{"groupId":"OG012","lowerLimit":"5.1","upperLimit":"17.3","value":"13.0"},{"groupId":"OG013","lowerLimit":"12.1","upperLimit":"18.3","value":"13.0"},{"groupId":"OG014","lowerLimit":"7.1","upperLimit":"23.7","value":"12.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"41"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"10"},{"groupId":"OG012","value":"9"},{"groupId":"OG013","value":"26"},{"groupId":"OG014","value":"12"}],"units":"Participants"}],"description":"PFS was defined as the time in weeks from Day 1 in Cycle 1 to first disease progression or death, whichever occurred earliest, as assessed by the investigator. Only deaths that occurred within 60 days of the last visit were considered in the analysis and result are presented based on Kaplan-Meier estimates. Progression as defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase from nadir in the sum of diameters of target lesions, unequivocal progression in non-target lesions, or the appearance of new lesions","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an intravenous (IV) infusion at a dose of 0.3 mg/kg of body weight.","id":"OG000","title":"Dose Escalation Part: 0.3 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.","id":"OG001","title":"Dose Escalation Part: 0.6 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.","id":"OG002","title":"Dose Escalation Part: 0.9 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.","id":"OG003","title":"Dose Escalation Part: 1.2 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.","id":"OG004","title":"Dose Escalation Part: 1.5 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.","id":"OG005","title":"Dose Escalation Part: 1.8 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG006","title":"Dose Escalation Part: 2.0 mg/kg"},{"description":"Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.","id":"OG007","title":"Dose Escalation Part: 2.2 mg/kg"},{"description":"Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG008","title":"Dose Expansion Part: Bladder Cancer"},{"description":"Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG009","title":"Dose Expansion Part: Cervical Cancer"},{"description":"Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG010","title":"Dose Expansion Part: Endometrial Cancer"},{"description":"Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG011","title":"Dose Expansion Part: Esophageal Cancer"},{"description":"Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG012","title":"Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)"},{"description":"Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG013","title":"Dose Expansion Part: Ovarian Cancer"},{"description":"Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG014","title":"Dose Expansion Part: Prostate Cancer"}],"paramType":"MEDIAN","populationDescription":"Participants with documented disease progression and/or death are included.","reportingStatus":"POSTED","timeFrame":"Day 1 to end of follow-up, up to a maximum of 60 weeks","title":"Dose Escalation and Expansion Part: Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Weeks"}